Mucins as biomarkers in cancer.

Kowa Chen; Klas Ola Blixt; Hans H. Wandall

doi:10.2217/9781780844206

Mucins as biomarkers in cancer.

Kowa Chen, Klas Ola Blixt, Hans H. Wandall

Glycomics Program

3 Citations (Scopus)

Abstract

Currently, only a few US FDA-approved serum cancer biomarkers are available. Most of these assays have 50-90% sensitivity and 50-80% specificity for the diagnosis of patients with advanced adenocarcinomas. These modest values reflect the expression and secretion of these antigens in several benign diseases.

Original language	English
Title of host publication	Mucins and Cancer
Number of pages	16
Place of Publication	London
Publisher	Future Medicine Ltd.
Publication date	1 Dec 2013
Pages	34-49
Chapter	3
ISBN (Electronic)	978-1-78084-420-6
DOIs	https://doi.org/10.2217/9781780844206
Publication status	Published - 1 Dec 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/9781780844206

Cite this

@inbook{14968a468b4a49d293d3d9976b08cdf2,

title = "Mucins as biomarkers in cancer.",

abstract = "Currently, only a few US FDA-approved serum cancer biomarkers are available. Most of these assays have 50-90% sensitivity and 50-80% specificity for the diagnosis of patients with advanced adenocarcinomas. These modest values reflect the expression and secretion of these antigens in several benign diseases.",

author = "Kowa Chen and Blixt, {Klas Ola} and Wandall, {Hans H.}",

year = "2013",

month = dec,

day = "1",

doi = "10.2217/9781780844206",

language = "English",

pages = "34--49",

booktitle = "Mucins and Cancer",

publisher = "Future Medicine Ltd.",

address = "United Kingdom",

}

TY - CHAP

T1 - Mucins as biomarkers in cancer.

AU - Chen, Kowa

AU - Blixt, Klas Ola

AU - Wandall, Hans H.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Currently, only a few US FDA-approved serum cancer biomarkers are available. Most of these assays have 50-90% sensitivity and 50-80% specificity for the diagnosis of patients with advanced adenocarcinomas. These modest values reflect the expression and secretion of these antigens in several benign diseases.

AB - Currently, only a few US FDA-approved serum cancer biomarkers are available. Most of these assays have 50-90% sensitivity and 50-80% specificity for the diagnosis of patients with advanced adenocarcinomas. These modest values reflect the expression and secretion of these antigens in several benign diseases.

U2 - 10.2217/9781780844206

DO - 10.2217/9781780844206

M3 - Book chapter

SP - 34

EP - 49

BT - Mucins and Cancer

PB - Future Medicine Ltd.

CY - London

ER -

Mucins as biomarkers in cancer.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this